ChemoCentryx, Inc.
TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH CCR2 ANTAGONISTS
Last updated:
Abstract:
Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist. In some embodiments, the CCR2 antagonist is used in monotherapy. In some embodiments, the CCR2 antagonist is used in combination therapy. In some embodiments, the additional therapeutic agent is a RAAS blocker and/or an endothelin receptor inhibitor.
Status:
Application
Type:
Utility
Filling date:
11 Aug 2020
Issue date:
7 Jan 2021